Boehringer Ingelheim continues search for Alzheimer’s treatment despite trial set-back

20 February 2018Boehringer Ingelheim have shifted their attention to a new compound to treat Alzheimer’s disease, after topline results of two Phase II trials of BI 409306 showed that it did not have efficacy when tested for Alzheimer’s disease.

There is hope for future success, as the company continues to search for a new treatment for Alzheimer’s disease, the most common form of dementia. Enrolment of a Phase II trial in Alzheimer’s Disease of a new compound, BI 425809, is planned for March and will include 600 trial participants..

Paola Barbarino, CEO of ADI, welcomed the ongoing effort of Boehringer Ingelheim to identify new or potential treatments of dementia, following a number of high profile set-backs in recent clinical research:

“We are of course disappointed to note the results from these trials but are pleased to support the resilience and dedication with which our colleagues at Boehringer Ingelheim will continue to search for treatments that will improve the lives of people with dementia and their families globally. Investment in research is urgently needed – now is the time for industry and others to ensure we go even further to address the impact of dementia.”

Dr Jan Poth, therapeutic area head of CNS and Immunology at Boehringer Ingelheim, said, “We recognize the immense anticipation around any progress in brain research that brings us closer to finding solutions for the many millions of people living with dementia.

However, this is what research is about . . . even these clinical trial results will add to the understanding of brain function and contribute to future progress in this area.”

Full results of the studies will be presented at the Alzheimer’s Association International Conference (AAIC) in July in Chicago, USA. For the first time in over 17 years, the ADI Conference will be held in the same week as AAIC, offering an unparalleled opportunity to hear from the biggest global gathering of researchers in dementia understanding science, care.  Find out more

Where next?